CureVac N.V. (0A9E.IL)
- Previous Close
3.2250 - Open
3.3300 - Bid 3.1780 x --
- Ask 3.5120 x --
- Day's Range
3.2900 - 3.3800 - 52 Week Range
2.3000 - 5.2800 - Volume
1,240 - Avg. Volume
7,769 - Market Cap (intraday)
835.544M - Beta (5Y Monthly) 2.81
- PE Ratio (TTM)
-- - EPS (TTM)
-1.5000 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.
www.curevac.comRecent News: 0A9E.IL
View MorePerformance Overview: 0A9E.IL
Trailing total returns as of 4/25/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0A9E.IL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0A9E.IL
View MoreValuation Measures
Market Cap
734.01M
Enterprise Value
228.40M
Trailing P/E
3.95
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.20
Price/Book (mrq)
0.92
Enterprise Value/Revenue
0.38
Enterprise Value/EBITDA
0.96
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-17.19%
Return on Equity (ttm)
-47.35%
Revenue (ttm)
37.61M
Net Income Avi to Common (ttm)
-301.18M
Diluted EPS (ttm)
-1.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
537.92M
Total Debt/Equity (mrq)
6.24%
Levered Free Cash Flow (ttm)
-210.05M